Micell Technologies Enrolls First Patients in China Stent Trial

Micell Technologies of North Carolina has started enrolling patients in a China registrational trial of its drug eluting stent, the MiStent SES ® . In 2013, Hefei Life Science, an arm of the Hefei Economic and Technological Development Area of Anhui Province, agreed to fund the trial; Hefei will be in charge of China distribution for the MiStent SES, once it is approved. More details.... Share this with colleagues: // //